In a report published Monday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. EW, but lowered its price target from $125.00 to $100.00.
Jefferies noted, “EW's 3Q miss was driven by TAVR weakness in the US due to timing around reimbursement, Cohort A approval, training, and seasonality; and Europe due to macroeconomic factors, as austerity cuts are negatively impacting procedures. Importantly, the underperformance in either geography does not appear related to structural factors or lower underlying demand. As such, we remain positive on the TAVR market opportunity. Maintain Buy.”
Edwards Lifesciences Corp. closed on Friday at $86.14.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in